Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 3176154559
clinical_inquiry_hub@lilly.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Medical Conditions

Alzheimer Disease


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.

Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2024 Apr 2029

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Remternetug;

Intervention Type : DRUG
Intervention Description : Administered SC

Intervention Arm Group : Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Warneford Hospital
    Oxford
    Oxfordshire
    OX3 7JX
  • Layton Medical Centre
    Blackpool
    Lancashire
    FY3 7EN
  • Re:Cognition Health - Birmingham
    Birmingham
    B16 8LT
  • Moorgreen Hospital
    Southampton
    Hampshire
    SO30 3JB
  • Abbeywell Surgery
    Romsey
    England
    SO51 7QN
  • Homecroft Surgery
    Redruth
    Cornwall
    TR16 4ET
  • Roborough Surgery
    Plymouth
    Devon
    PL6 6PH
  • ReMind UK
    Bath
    Bath And North East Somerset
    BA1 3NG
  • St Pancras Clinical Research
    London
    London, City Of
    EC2Y 8EA
  • Marine Lake Medical Practice
    West Kirby
    Wirral
    CH48 5AA
  • NIHR Manchester Clinical Research Facility
    Manchester
    M13 9WL
  • Scottish Brain Sciences
    Edinburgh
    Edinburgh, City Of
    EH12 5PJ
  • NeuroClin
    Motherwell
    Great Britain
    ML1 4UF

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 3176154559
clinical_inquiry_hub@lilly.com



The study is sponsored by Eli Lilly and Company




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06653153
Last updated 04 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.